Centurion Corporation Expands into Australian Key Worker Accommodation with BUY Rating and S$1.85 Target Price

Centurion Corporation Expands into Australian Key Worker Accommodation with BUY Rating and S$1.85 Target Price

Yik Ban Chong

26 May 2026  |    11 views

Strong Revenue Growth Driven by Strategic Acquisitions

Centurion Corporation Limited (CCL), a leading provider of purpose-built worker accommodation (PBWA) and purpose-built student accommodation (PBSA) across multiple markets, has delivered robust first-quarter results for FY2026, with revenue surging 30% year-on-year to S$89.4 million. The company operates accommodation facilities across Singapore, Malaysia, the United Kingdom, and Australia, serving both workers and students with quality housing solutions.


Strategic Entry into Australian Key Worker Market

CCL has made a significant strategic move by entering the Australian key worker accommodation sector through two acquisitions in April 2026. The company acquired 321 beds in Karratha and 125 beds in South Hedland, both located in the Pilbara region, which produces approximately 96% of Australia’s iron ore exports. These key worker accommodations are expected to contribute approximately S$6.5 million in FY2026 revenue, representing 2% of FY2025 revenue, assuming acquisitions complete from July 2026.


The Positives: Acquisition-Led Growth Strategy

Asset acquisitions continue to drive substantial growth across CCL’s portfolio. Malaysia PBWA revenue increased 30% year-on-year to S$6.2 million, primarily driven by the acquisition of the Harum Megah portfolio with 7,000 beds in September 2025, expanding Malaysia capacity by 24%. Singapore and Australia revenue also experienced significant growth of 29% and 107% year-on-year respectively. The Singapore growth was supported by Centurion Accommodation REIT’s acquisition of the remaining 55% stake in the 8,000-bed Westlite Mandai, whilst Australia benefited from the newly completed 732-bed Sydney PBSA, EPIISOD Macquarie Park, which increased Australia’s capacity by 82%.

High occupancy rates remain a key strength, with Singapore PBWA maintaining healthy occupancy at 95% in 1Q26, despite a slight dip from 98% due to new bed ramp-up. UK PBSA occupancy remained strong at 98%, supported by continued rising demand from international students.


The Negatives: Malaysian Market Challenges

The primary concern lies in Malaysia, where PBWA occupancy declined to 73% in 1Q26 from 80% in the previous year. This decrease reflects the government’s advancement of policies to curb foreign labour dependency, resulting in approximately 10% reduction in the foreign workforce. However, longer-term prospects remain supported by the enforcement of Act 446, which mandates regulated accommodation for all workers.


Enhanced Financial Outlook

Phillip Securities Research maintains a BUY recommendation with a raised target price of S$1.85, up from the previous S$1.81. The analysts have increased FY2026 revenue and adjusted PATMI forecasts by 6% and 8% respectively, driven by higher expected contributions from the management contract for EPIISOD Macquarie Park and the Australian key worker accommodation acquisitions. Management service fees from CAREIT contributed S$7 million to 1Q26 revenue, compared to just S$0.2 million in 1Q25, with expectations for CAREIT management fees to contribute approximately S$16 million to FY2026 PATMI, representing 15% of FY2025 adjusted PATMI.


Frequently Asked Questions

Q: What drove Centurion Corporation's strong revenue growth in 1Q26?

A: Revenue increased 30% year-on-year to S$89.4 million, driven by growth across all PBWA and PBSA segments, including additional revenue from the 55% stake in Westlite Mandai and 5,460 new beds from AEI expansion.

Q: What is Centurion Corporation's new strategic initiative in Australia?

A: CCL entered the Australian key worker accommodation market through two acquisitions in April 2026: 321 beds in Karratha and 125 beds in South Hedland, both in the Pilbara region which produces 96% of Australia's iron ore exports.

Q: What is Phillip Securities Research's recommendation and target price?

A: Phillip Securities Research maintains a BUY rating with a raised target price of S$1.85, increased from the previous S$1.81.

Q: How are occupancy rates performing across different markets?

A: Singapore PBWA occupancy remains healthy at 95%, UK PBSA occupancy is strong at 98%, but Malaysia PBWA occupancy declined to 73% from 80% due to government policies reducing foreign workforce dependency.

Q: What acquisitions have driven growth in Malaysia and Singapore?

A: Malaysia growth was driven by the Harum Megah portfolio acquisition of 7,000 beds in September 2025, whilst Singapore benefited from CAREIT's acquisition of the remaining 55% stake in the 8,000-bed Westlite Mandai.

Q: How significant is the contribution from management services?

A: Management service fees from CAREIT contributed S$7 million to 1Q26 revenue compared to S$0.2 million in 1Q25, with expectations for approximately S$16 million contribution to FY2026 PATMI.

Q: What are the longer-term prospects for the Malaysian market despite current challenges?

A: Despite current occupancy decline due to foreign workforce reduction, longer-term prospects are supported by the enforcement of Act 446, which mandates regulated accommodation for all workers.

Q: How much revenue are the Australian key worker accommodations expected to contribute?

A: The Australian key worker accommodations are estimated to contribute approximately S$6.5 million in FY2026 revenue, representing 2% of FY2025 revenue, assuming acquisitions complete from July 2026.

Factsheets

 

This article has been auto-generated using PhillipGPT. It is based on a report by a Phillip Securities Research analyst.

 

Disclaimer

These commentaries are intended for general circulation and do not have regard to the specific investment objectives, financial situation and particular needs of any person. Accordingly, no warranty whatsoever is given and no liability whatsoever is accepted for any loss arising whether directly or indirectly as a result of any person acting based on this information. You should seek advice from a financial adviser regarding the suitability of any investment product(s) mentioned herein, taking into account your specific investment objectives, financial situation or particular needs, before making a commitment to invest in such products.

Opinions expressed in these commentaries are subject to change without notice. Investments are subject to investment risks including the possible loss of the principal amount invested. The value of units in any fund and the income from them may fall as well as rise. Past performance figures as well as any projection or forecast used in these commentaries are not necessarily indicative of future or likely performance.

Phillip Securities Pte Ltd (PSPL), its directors, connected persons or employees may from time to time have an interest in the financial instruments mentioned in these commentaries.

The information contained in these commentaries has been obtained from public sources which PSPL has no reason to believe are unreliable and any analysis, forecasts, projections, expectations and opinions (collectively the “Research”) contained in these commentaries are based on such information and are expressions of belief only. PSPL has not verified this information and no representation or warranty, express or implied, is made that such information or Research is accurate, complete or verified or should be relied upon as such. Any such information or Research contained in these commentaries are subject to change, and PSPL shall not have any responsibility to maintain the information or Research made available or to supply any corrections, updates or releases in connection therewith. In no event will PSPL be liable for any special, indirect, incidental or consequential damages which may be incurred from the use of the information or Research made available, even if it has been advised of the possibility of such damages. The companies and their employees mentioned in these commentaries cannot be held liable for any errors, inaccuracies and/or omissions howsoever caused. Any opinion or advice herein is made on a general basis and is subject to change without notice. The information provided in these commentaries may contain optimistic statements regarding future events or future financial performance of countries, markets or companies. You must make your own financial assessment of the relevance, accuracy and adequacy of the information provided in these commentaries.

Views and any strategies described in these commentaries may not be suitable for all investors. Opinions expressed herein may differ from the opinions expressed by other units of PSPL or its connected persons and associates. Any reference to or discussion of investment products or commodities in these commentaries is purely for illustrative purposes only and must not be construed as a recommendation, an offer or solicitation for the subscription, purchase or sale of the investment products or commodities mentioned.

This advertisement has not been reviewed by the Monetary Authority of Singapore.

Related Articles

KOSPI Vs KOSDAQ: Which South Korean Market Is Right For You?

This is the second part of our South Korean Market Series — New to South...

  26 May 2026  |    25 views

NetLink NBN Trust Maintains Steady Cash Flow Despite Rising Costs, Target Price Raised to S$0.96

Company Overview NetLink NBN Trust operates as Singapore’s dominant fibre network infrastructure provider, managing the...

  26 May 2026  |    8 views

Sea Ltd. Maintains Strong Growth Trajectory with Strategic Investment Focus, BUY Rating and US$170 Target Price

Company Overview Sea Ltd. operates as a leading digital entertainment, e-commerce, and digital financial services...

  26 May 2026  |    4 views

IMPORTANT INFORMATION

This material is provided by Phillip Capital Management (S) Ltd (“PCM”) for general information only and does not constitute a recommendation, an offer to sell, or a solicitation of any offer to invest in any of the exchange-traded fund (“ETF”) or the unit trust (“Products”) mentioned herein. It does not have any regard to your specific investment objectives, financial situation and any of your particular needs. You should read the Prospectus and the accompanying Product Highlights Sheet (“PHS”) for key features, key risks and other important information of the Products and obtain advice from a financial adviser (“FA“) pursuant to a separate engagement before making a commitment to invest in the Products. In the event that you choose not to obtain advice from a FA, you should assess whether the Products are suitable for you before proceeding to invest. A copy of the Prospectus and PHS are available from PCM, any of its Participating Dealers (“PDs“) for the ETF, or any of its authorised distributors for the unit trust managed by PCM.  

An ETF is not like a typical unit trust as the units of the ETF (the “Units“) are to be listed and traded like any share on the Singapore Exchange Securities Trading Limited (“SGX-ST”). Listing on the SGX-ST does not guarantee a liquid market for the Units which may be traded at prices above or below its NAV or may be suspended or delisted. Investors may buy or sell the Units on SGX-ST when it is listed. Investors cannot create or redeem Units directly with PCM and have no rights to request PCM to redeem or purchase their Units. Creation and redemption of Units are through PDs if investors are clients of the PDs, who have no obligation to agree to create or redeem Units on behalf of any investor and may impose terms and conditions in connection with such creation or redemption orders. Please refer to the Prospectus of the ETF for more details.  

Investments are subject to investment risks including the possible loss of the principal amount invested. The purchase of a unit in a fund is not the same as placing your money on deposit with a bank or deposit-taking company. There is no guarantee as to the amount of capital invested or return received. The value of the units and the income accruing to the units may fall or rise. Past performance is not necessarily indicative of the future or likely performance of the Products. There can be no assurance that investment objectives will be achieved.  

Where applicable, fund(s) may invest in financial derivatives and/or participate in securities lending and repurchase transactions for the purpose of hedging and/or efficient portfolio management, subject to the relevant regulatory requirements. PCM reserves the discretion to determine if currency exposure should be hedged actively, passively or not at all, in the best interest of the Products.  

The regular dividend distributions, out of either income and/or capital, are not guaranteed and subject to PCM’s discretion. Past payout yields and payments do not represent future payout yields and payments. Such dividend distributions will reduce the available capital for reinvestment and may result in an immediate decrease in the net asset value (“NAV”) of the Products. Please refer to <www.phillipfunds.com> for more information in relation to the dividend distributions.  

The information provided herein may be obtained or compiled from public and/or third party sources that PCM has no reason to believe are unreliable. Any opinion or view herein is an expression of belief of the individual author or the indicated source (as applicable) only. PCM makes no representation or warranty that such information is accurate, complete, verified or should be relied upon as such. The information does not constitute, and should not be used as a substitute for tax, legal or investment advice.  

The information herein are not for any person in any jurisdiction or country where such distribution or availability for use would contravene any applicable law or regulation or would subject PCM to any registration or licensing requirement in such jurisdiction or country. The Products is not offered to U.S. Persons. PhillipCapital Group of Companies, including PCM, their affiliates and/or their officers, directors and/or employees may own or have positions in the Products. Any member of the PhillipCapital Group of Companies may have acted upon or used the information, analyses and opinions herein before they have been published. 

This advertisement has not been reviewed by the Monetary Authority of Singapore.  

 

Phillip Capital Management (S) Ltd (Co. Reg. No. 199905233W)  
250 North Bridge Road #06-00, Raffles City Tower ,Singapore 179101 
Tel: (65) 6230 8133 Fax: (65) 65383066 www.phillipfunds.com